comparemela.com

Latest Breaking News On - Biospace - Page 3 : comparemela.com

Qilian International Holding Group Limited Announces Inclusion of 16 Products into China s National Reimbursement Drugs List

Published: Apr 13, 2021 Jiuquan, China, April 13, 2021 (GLOBE NEWSWIRE) Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced that 16 of its products have been included in the latest version of the National Reimbursement Drugs List in China, such as aspirin enteric-coated tablets for coronary heart disease treatment, and nitrofurantoin enteric-coated tablets for the treatment of urinary tract infections. In addition, 10 out of these 16 products have been included in the latest version of the National Essential Medicines List in China. National Reimbursement Drug List is the list of products eligible for reimbursement in China, as maintained by the National Healthcare Commission of China. The National Essential Medicines List is one of the core contents of the essential medicines system. The system requires that all government-run primary health care institutions be equi

Adicet Bio Appoints Dr Blake Aftab as Vice President of Research

Published: Apr 13, 2021 MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE) Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Blake Aftab, Ph.D., as Vice President of Research. Dr. Aftab will lead Adicet’s research group and will further develop existing and new opportunities for the Company’s gamma delta T cell platform. “We are very excited to have Blake join Adicet, and lead our research team as we advance the clinical development of ADI-001 and rapidly develop a deep pipeline of “off-the-shelf” gamma delta T cell therapies,” said Stewart Abbot, Chief Scientific and Operating Officer of Adicet. “Blake has committed his career, with notable success, to researching and developing cell therapies across a variety of indications including oncology, infectious disease, and autoimmune conditions, while also buildin

BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions

BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions - read this article along with other careers information, tips and advice on BioSpace

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.